Psoriatic Arthritis
Conference Coverage
Oral tofacitinib scores against psoriasis in phase III trial
Key clinical point: Multiple measures of quality of life and disease burden improved similarly in psoriasis patients regardless of whether they...
Conference Coverage
Secukinumab tames psoriatic arthritis in FUTURE 2 trial
Key clinical point: Secukinumab could prove to be a major new therapy for psoriatic arthritis. Major finding: After 24 weeks, a response of at...
Conference Coverage
Few psoriatic arthritis patients achieve minimal disease activity on methotrexate
Key clinical point: It may be time to rethink methotrexate’s role as first-line therapy for psoriatic arthritis. Major finding: Only 17.4% of...
News
TNF-alpha blockers effective in sustaining reduced PsA activity
Key clinical point: A majority of PsA patients seen in a clinical setting can achieve minimal disease activity on TNF-alpha inhibitors. Major...
Conference Coverage
Psoriasis is independently associated with advanced liver fibrosis
Key clinical point: Noninvasive screening for advanced hepatic fibrosis may be in order for older patients with mild psoriasis never treated...
News
Psoriasis: Brodalumab maintains efficacy through 144 weeks
Key clinical point: The investigational interleukin-17 receptor A inhibitor brodalumab maintained strong clinical efficacy throughout 144 weeks of...
Conference Coverage
Certolizumab achieves sustained skin improvement in psoriatic arthritis
Key clinical point: Certolizumab pegol maintains sustained improvement in the dermatologic manifestations of psoriatic arthritis through 96 weeks...
News
Veterans more likely to have arthritis at any age
News
Chronic inflammatory disease patients at greater risk of major CV events
Key clinical point: Patients with RA, PsA, and psoriasis have similarly elevated risk for major adverse cardiovascular events when compared with...
News
Current use of COX-2 inhibitors linked to increased mortality after ischemic stroke
Key clinical point:Consideration should be given to using treatment options other than COX-2 inhibitors in patients with a high future risk of...